tert-butyl 4-(2-oxo-3,4-dihydroquinolin-1(2H)-yl)piperidine-1-carboxylate | 162046-30-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: tert-butyl 4-(2-oxo-3,4-dihydroquinolin-1(2H)-yl)piperidine-1-carboxylate
• 英文别名: 1-((1-t-butyloxycarbonyl)piperidin-4-yl)-tetrahydroquinolinone；1,1-Dimethylethyl 4-(3,4-dihydro-2-oxo-1(2H)-quinolinyl)-1-piperidinecarboxylate；tert-butyl 4-(2-oxo-3,4-dihydroquinolin-1-yl)piperidine-1-carboxylate
• CAS: 162046-30-2
• 化学式: C₁₉H₂₆N₂O₃
• 分子量: 330.427
• InChiKey: RGUDDTJNCHDPGC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  49.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-(2-oxo-3,4-dihydroquinolin-1(2H)-yl)piperidine-1-carboxylate 在 三氟乙酸 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 生成 1-(1-(3-(3-(4-bromophenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl)-2-hydroxypropyl)piperidin-4-yl)-3,4-dihydroquinolin-2(1H)-one
  参考文献：
  名称：

  The SAR of 4-substituted (6,6-bicyclic) piperidine cathepsin S inhibitors

  摘要：

  A series of competitive, reversible cathepsin S (CatS) inhibitors was investigated. An earlier disclosure detailed the discovery of the 4-(2-keto-1-benzimidazolinyl)-piperidin-1-yl moiety as an effective replacement for the 4-arylpiperazin-1-yl group found in our screening hit. Continued investigation into replacements for the 4-aryl piperazine resulted in the identification of potentially useful CatS inhibitors with enzymatic and Cellular activity similar to that of JNJ 10329670 as disclosed in a previous publication. (C) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.01.038
• 作为产物：
  描述：

  ethyl (E)-3-(2-aminophenyl)acrylate 在 palladium on activated charcoal sodium hydroxide 、 氢气 、 三乙酰氧基硼氢化钠 、 溶剂黄146 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 甲醇 、 二氯甲烷 、 乙酸乙酯 为溶剂， 生成 tert-butyl 4-(2-oxo-3,4-dihydroquinolin-1(2H)-yl)piperidine-1-carboxylate
  参考文献：
  名称：

  The SAR of 4-substituted (6,6-bicyclic) piperidine cathepsin S inhibitors

  摘要：

  A series of competitive, reversible cathepsin S (CatS) inhibitors was investigated. An earlier disclosure detailed the discovery of the 4-(2-keto-1-benzimidazolinyl)-piperidin-1-yl moiety as an effective replacement for the 4-arylpiperazin-1-yl group found in our screening hit. Continued investigation into replacements for the 4-aryl piperazine resulted in the identification of potentially useful CatS inhibitors with enzymatic and Cellular activity similar to that of JNJ 10329670 as disclosed in a previous publication. (C) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.01.038

文献信息

• Benzoxazinone and benzopyrimidinone piperidinyl tocolytic oxytocin
  申请人：Merck & Co., Inc.

  公开号：US05665719A1

  公开（公告）日：1997-09-09

  Compounds of the formula ##STR1## X is --O--, --NH-- and --NR.sup.8 --; Y is --CH.sub.2 --, --CHR.sup.8 -- and --C(R.sup.8).sub.2 --; R.sup.1 is camphor-10-yl, C.sub.1-5 alkoxyl, styryl, hydroxystyryl, furyl, unsubstituted or substituted thienyl, naphthyl, indolyl, tetrahydronaphthyl, unsubstituted, mono- or di-substituted pyridyl, pyrazinyl, unsubstituted or substituted cyclohexyl where the substituent is R.sup.4, and unsubstituted or substituted phenyl where the substituents on phenyl are R.sup.5, R.sup.6 and R.sup.7 ; R.sup.2 is hydrogen, C.sub.1-5 alkoxy, C.sub.1-5 alkyl, amino, C.sub.1-5 alkylcarbonylamino, nitro or halogen; R.sup.3 is hydrogen, C.sub.1-5 alkoxycarbonyl, cyano or carbamoyl; R.sup.4 is one to two of hydrogen, oxo, hydroxy, C.sub.1-5 alkoxy, C.sub.1-5 alkoxycarbonylamino-C.sub.1-5 alkyl and amino-C.sub.1-5 alkyl; R.sup.5, R.sup.6 are each independently selected from hydrogen, halogen, C.sub.1-5 alkyl, hydroxyl and C.sub.1-5 alkoxy; R.sup.7 is ##STR2## W is CO or SO.sub.2 ; and m is an integer from 0 to 1. Such compounds as useful as oxytocin and vasopressin receptor antagonists.

  该公式化合物的翻译如下： X为--O--，--NH--和--NR.sup.8--；Y为--CH.sub.2--，--CHR.sup.8--和--C(R.sup.8).sub.2--；R.sup.1为樟脑-10-基，C.sub.1-5烷氧基，苯乙烯基，羟基苯乙烯基，呋喃基，未取代或取代噻吩基，萘基，吲哚基，四氢萘基，未取代，单取代或双取代吡啶基，吡嗪基，未取代或取代的环己基，其中取代基为R.sup.4，以及未取代或取代的苯基，苯基上的取代基为R.sup.5，R.sup.6和R.sup.7；R.sup.2为氢，C.sub.1-5烷氧基，C.sub.1-5烷基，氨基，C.sub.1-5烷基羰基氨基，硝基或卤素；R.sup.3为氢，C.sub.1-5烷氧羰基，氰基或氨基甲酰基；R.sup.4为氢，氧代，羟基，C.sub.1-5烷氧基，C.sub.1-5烷氧羰基氨基-C.sub.1-5烷基和氨基-C.sub.1-5烷基中的一种或两种；R.sup.5，R.sup.6分别独立选择自氢，卤素，C.sub.1-5烷基，羟基和C.sub.1-5烷氧基；R.sup.7为##STR2## W为CO或SO.sub.2；m为0到1的整数。这些化合物可用作催产素和抗利尿激素受体拮抗剂。
• NIS-mediated oxidative arene C(sp²)–H amidation toward 3,4-dihydro-2(1<i>H</i>)-quinolinone, phenanthridone, and <i>N</i>-fused spirolactam derivatives
  作者：Lingang Wu、Yanan Hao、Yuxiu Liu、Qingmin Wang

  DOI：10.1039/c9ob01277j

  日期：——

  A new radical-mediated intramolecular arene C(sp2)-H amidation of 3-phenylpropanamides or [1,1'-biphenyl]-2-carboxamides was developed to prepare a series of 3,4-dihydro-2(1H)-quinolinone and phenanthridone derivatives in moderate to excellent yields (33-94%). Spirolactams could also be obtained using this protocol.

  一种新的自由基介导的3-苯基丙酰胺或[1,1'-联苯] -2-羧酰胺的分子内芳烃C（sp2）-H酰胺化反应制备了一系列3,4-二氢-2（1H）-喹啉酮和菲啶酮衍生物的收率中等至优异（33-94％）。螺内酰胺也可以使用该方案获得。
• Quinolinone derivatives and their use to treat pain
  申请人：EURO-CELTIQUE S.A.

  公开号：EP1997818A2

  公开（公告）日：2008-12-03

  A compound of the having the general formula (I) or general formula (II) wherein Z, A, B, C, R1, R2, Q1 and W1 and n are as described herein.

  具有通式（I）或通式（II）的化合物，其中 Z、A、B、C、R1、R2、Q1 和 W1 及 n 如本文所述。
• BENZOXAZINONE AND BENZOPYRIMIDINONE PIPERIDINYL TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS
  申请人：Merck & Co., Inc.

  公开号：EP0714299B1

  公开（公告）日：2002-04-24
• NOCICEPTIN ANALOGS
  申请人：Goehring R. Richard

  公开号：US20090253727A1

  公开（公告）日：2009-10-08

  A compound of the having the general formula (I) or general formula (II): wherein Z, A, B, C, R 1 , R 2 , Q, W, and n are as described herein.